PDS Biotechnology Reports First Quarter 2019 Financial Results and Provides Business Update
14 mai 2019 16h10 HE
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., May 14, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of...
PDS Biotechnology Appoints Stephen Glover to its Board of Directors
08 avr. 2019 08h00 HE
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., April 08, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing novel multifunctional immunotherapeutic...
PDS Biotechnology Completes Merger with Edge Therapeutics
18 mars 2019 06h00 HE
|
PDS Biotechnology Corporation
PRINCETON, N.J., March 18, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”), a clinical-stage immuno-oncology company pioneering the development of novel multifunctional...
Edge Therapeutics Announces Full Year 2018 Financial Results
21 févr. 2019 06h15 HE
|
Edge Therapeutics, Inc.
BERKELEY HEIGHTS, N.J., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq: EDGE) today announced financial results for the full-year ended December 31, 2018. Financial Results ...
Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company
26 nov. 2018 06h30 HE
|
Edge Therapeutics, Inc.
-Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer- -Growing product pipeline utilizing Versamune®, a...
Edge Therapeutics Reports Third Quarter 2018 Financial Results
01 nov. 2018 06h00 HE
|
Edge Therapeutics, Inc.
BERKELEY HEIGHTS, N.J., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq: EDGE) today announced financial results for the quarter ended September 30, 2018. Third Quarter...
Edge Therapeutics Reports Second Quarter 2018 Financial Results
01 août 2018 06h00 HE
|
Edge Therapeutics, Inc.
BERKELEY HEIGHTS, N.J., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced financial results for the quarter ended June 30, 2018. Second Quarter...
Edge Therapeutics Announces Updated Results from Phase 3 NEWTON 2 Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
27 juin 2018 16h30 HE
|
Edge Therapeutics, Inc.
BERKELEY HEIGHTS, N.J., June 27, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced updated results from its ongoing analyses of the Phase 3 NEWTON 2 study of EG-1962 in...
Edge Therapeutics Reports First Quarter 2018 Financial Results
01 mai 2018 06h30 HE
|
Edge Therapeutics, Inc.
BERKELEY HEIGHTS, N.J., May 01, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced financial results for the quarter ended March 31, 2018. First Quarter Financial...
Edge Therapeutics Announces Review of Strategic Alternatives
30 avr. 2018 07h00 HE
|
Edge Therapeutics, Inc.
BERKELEY HEIGHTS, N.J., April 30, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced that its Board of Directors is conducting a comprehensive review of strategic...